tirzepatide shortage resolved FDA Says Compounded Must Exit the Market FDA Announces End of Tirzepatide

Failing to protect from light while less critical than temperature control, can contribute to degradation over time

Experienced clinical teams check blood pressure, track metabolic markers, and review how medications work together throughout the process

Patients should not advance doses if experiencing significant gastrointestinal symptoms

They mimic hormones your gut naturally releases after eating

This personalized approach reduces trial-and-error supplementation and accelerates the metabolic benefits of tirzepatide therapy

Tirzepatide injections, marketed under the brand names Zepbound and Mounjaro by Eli Lilly, can no longer be compounded by 503A Compounding Pharmacies or 503B Outsourcing Facilities, with limited exceptions (detailed below)